Plain-English translation of NCT05013632 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety tracking study for pregnant women who received monoclonal antibodies or antiviral drugs to treat COVID-19 during pregnancy. Researchers want to understand how these medications affect the health of both mother and baby, since most of these treatments are newer and haven't been extensively studied in pregnancy. The study will follow women and their infants for up to one year after birth.
Many new COVID-19 medications have been developed quickly, but we don't yet have enough scientific evidence about whether they are safe during pregnancy for either the mother or the developing baby. This registry aims to gather real-world safety information to help protect pregnant women and their infants in the future.
You likely qualify if…
You likely don't qualify if…
You would enroll in this registry by visiting a website and answering questions about your pregnancy, COVID-19 illness, and any medications you received. You would share medical information about your pregnancy and your baby's health after birth. The study team would follow up with you and your baby's doctor periodically until your baby is one year old to collect information about your baby's growth, development, and health.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Enrollment target
~2,000 participants
Started
December 2021
Primary completion
September 2027
Age range
18 Years – 50 Years
Sex
Female only
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cheryl Renz, MD
Pregistry
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.